Pamela Drullinsky
About
Pamela Drullinsky is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine.
According to data from OpenAlex, Pamela Drullinsky has authored 57 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Pamela Drullinsky's work include Cancer Treatment and Pharmacology (26 papers), Advanced Breast Cancer Therapies (22 papers) and HER2/EGFR in Cancer Research (18 papers). Pamela Drullinsky is often cited by papers focused on Cancer Treatment and Pharmacology (26 papers), Advanced Breast Cancer Therapies (22 papers) and HER2/EGFR in Cancer Research (18 papers). Pamela Drullinsky collaborates with scholars based in United States, Spain and Canada. Pamela Drullinsky's co-authors include Monika Engelhardt, Malcolm A.S. Moore, J G Guillem, Richard T. Silver, Karen L. MacKenzie, Florence Lerebours, Stephen Chia, Hope S. Rugo, Nicholas C. Turner and Dejan Juric and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Pamela Drullinsky
56 papers receiving 1.3k citations
Hit Papers
Peers
Pamela Drullinsky
Betty Gardie France
James P. Solomon United States
Shigeki Nanjo Japan
Sudha Parasuraman United States
Francesco Atzori Italy
Joost S.P. Vermaat Netherlands
Kaname Yamashita Japan
Lesley Mathews United States
Michele Massimino Italy
Luc Morat France
Citations per year, relative to Pamela Drullinsky Pamela Drullinsky (= 1×)
peers
Betty Gardie
Countries citing papers authored by Pamela Drullinsky
Since
Specialization
Citations
This map shows the geographic impact of Pamela Drullinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela Drullinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela Drullinsky more than expected).
Fields of papers citing papers by Pamela Drullinsky
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Pamela Drullinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela Drullinsky. The network helps show where Pamela Drullinsky may publish in the future.
Co-authorship network of co-authors of Pamela Drullinsky
This figure shows the co-authorship network connecting the top 25 collaborators of Pamela Drullinsky. A scholar is included among the top collaborators of Pamela Drullinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela Drullinsky. Pamela Drullinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yu, Anthony F., Chau T. Dang, Chaya S. Moskowitz, et al.. (2025). Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy. JACC CardioOncology. 7(4). 430–441.
2.
Chia, Stephen, Patrick Neven, Eva Ciruelos, et al.. (2023). Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.. Journal of Clinical Oncology. 41(16_suppl). 1078–1078.
3.
Kumar, Anita, Carla Casulo, Erel Joffe, et al.. (2022). Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design. Leukemia & lymphoma. 63(12). 2889–2896.
4.
Rugo, Hope S., Florence Lerebours, Eva Ciruelos, et al.. (2021). Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet Oncology. 22(4). 489–498.
5.
Lin, Richard J., Colette Owens, Esther Drill, et al.. (2021). Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. Haematologica. 107(5). 1144–1152.
6.
Dent, Susan, Javier Cortés, Young‐Hyuck Im, et al.. (2020). Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Annals of Oncology. 32(2). 197–207.
7.
Wang, Diana G., Dulce M. Barrios, Victoria Blinder, et al.. (2020). Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer. Breast Cancer Research and Treatment. 183(1). 227–237.
8.
Drullinsky, Pamela & Sara A. Hurvitz. (2020). Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. Breast Cancer Research and Treatment. 181(2). 233–248.
9.
Borchmann, Sven, Erel Joffe, Craig H. Moskowitz, et al.. (2019). Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 133(20). 2121–2129.
10.
Baselga, José, Susan Dent, Javier Cortés, et al.. (2018). Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. Journal of Clinical Oncology. 36(18_suppl). LBA1006–LBA1006.
11.
Batlevi, Connie Lee, Caitlin M. Stewart, Paul A. Hamlin, et al.. (2018). Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.. Journal of Clinical Oncology. 36(15_suppl). 7520–7520.
12.
Kumar, Anita, Andrew D. Zelenetz, Connie Lee Batlevi, et al.. (2018). Initial Results of a Phase II Study of Sequential Chemotherapy and Lenalidomide Followed By Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma. Blood. 132(Supplement 1). 2880–2880.
13.
Smyth, Lillian M., Neil M. Iyengar, Sujata Patil, et al.. (2016). Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Research and Treatment. 158(1). 91–97.
14.
Iyengar, Neil M., Monica Fornier, Steven Sugarman, et al.. (2015). A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer. 16(2). 87–94.
15.
Casulo, Carla, Craig H. Moskowitz, Alison J. Moskowitz, et al.. (2014). Ofatumumab-Bendamustine As First Line Treatment for Elderly Patients with Mantle Cell Lymphoma: A Phase II Risk Adapted Design with Comprehensive Geriatric Assessment. Blood. 124(21). 1751–1751.
16.
Landau, Heather, Neeta Pandit‐Taskar, Hani Hassoun, et al.. (2011). Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia & lymphoma. 53(2). 275–281.
17.
Gucalp, Ayca, SM Tolaney, SJ Isakoff, et al.. (2011). TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). TPS122–TPS122.
18.
Sugarman, Steven, Carolyn Wasserheit, Tiffany A. Troso-Sandoval, et al.. (2008). A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Research and Treatment. 115(3). 609–612.
19.
Drullinsky, Pamela, et al.. (1998). A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia. 12(6). 865–868.
20.
Engelhardt, Monika, et al.. (1998). Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia. 12(1). 13–24.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Betty Gardie Breakdown of academic impact, for papers by James P. Solomon Breakdown of academic impact, for papers by Shigeki Nanjo Breakdown of academic impact, for papers by Sudha Parasuraman Breakdown of academic impact, for papers by Francesco Atzori Breakdown of academic impact, for papers by Joost S.P. Vermaat Breakdown of academic impact, for papers by Kaname Yamashita Breakdown of academic impact, for papers by Lesley Mathews Breakdown of academic impact, for papers by Michele Massimino Breakdown of academic impact, for papers by Luc Morat